aclacinomycin has been researched along with Bladder Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akazawa, N; Asahi, T; Hayata, S; Okita, K; Takeda, K; Tsugawa, M | 1 |
| Kubota, Y; Miura, T; Sakuramoto, T | 1 |
2 other study(ies) available for aclacinomycin and Bladder Cancer
| Article | Year |
|---|---|
[Treatment of advanced bladder cancer with intra-arterial infusion of cisplatinum (CDDP) and aclacinomycin (ACR), combined with angiotensin II].
Topics: Aclarubicin; Aged; Aged, 80 and over; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Naphthacenes; Remission Induction; Urinary Bladder Neoplasms | 1987 |
[Sensitivity tests of anti-cancer drugs with human tumor stem cell assay. 2. The results in renal cell carcinoma and urothelial carcinoma].
Topics: Aclarubicin; Antineoplastic Agents; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colony-Forming Units Assay; Doxorubicin; Drug Evaluation, Preclinical; Humans; Kidney Neoplasms; Kidney Pelvis; Naphthacenes; Tumor Stem Cell Assay; Urinary Bladder Neoplasms; Vinblastine | 1985 |